Navigation Links
Inverness Medical Innovations Announces Third Quarter 2008 Results
Date:10/29/2008

excluding such charges and income from income or loss allows

investors and management to evaluate and compare the Company's

operating results from continuing operations from period to period

in a meaningful and consistent manner. Due to the frequency of

their occurrence in its business, the Company does not adjust net

income or loss for the costs associated with litigation, including

payments made or received through settlements. It should be noted

that "net income or loss on an adjusted cash basis" is not a

standard financial measurement under accounting principles generally

accepted in the United States of America ("GAAP") and should not be

considered as an alternative to net income or loss or cash flow from

operating activities, as a measure of liquidity or as an indicator

of operating performance or any measure of performance derived in

accordance with GAAP. In addition, all companies do not calculate

non-GAAP financial measures in the same manner and, accordingly,

"net income or loss on an adjusted cash basis" presented in this

press release may not be comparable to similar measures used by

other companies.

(b) Amortization expense of $60.0 million and $19.9 million in the third

quarter of 2008 and 2007 GAAP results, respectively, including $10.5

million and $7.5 million charged to cost of sales, $1.0 million and

$0.6 million charged to research and development and $48.3 million

and $11.7 million charged to selling, general and administrative, in

the respective quarters, with $0.2 million and $0.1 million charged

through equity earnings of unconsolidated entities, net of tax

during the respective quarters.

( c ) Restructuring charges associated with the decisi
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET October 29, 2008 to Discuss Third Quarter 2008 Results
2. Inverness Medical Innovations to Present at the UBS Global Life Sciences Conference on September 22, 2008
3. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
4. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
5. Inverness Medical Innovations to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 9, 2008
6. Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008
7. Inverness Medical Innovations to Present at Canaccord Adams 28th Annual Growth Conference on August 12, 2008
8. Inverness Medical Innovations Announces Second Quarter 2008 Results
9. Inverness Medical Innovations to Present at Jefferies 2nd Annual Healthcare Conference held on June 25, 2008
10. Inverness Medical Innovations to Present at 7th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference on June 12, 2008
11. Inverness Medical Innovations to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 28, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... (Nasdaq and SWX: BMRN) announced today that AnGes ... Japan, has,received approval for its Marketing Application for ... and Welfare,(MHLW) for the treatment of patients with ... to work with AnGes in bringing the first ...
... Company Cites Important Progress With Needle-free Vaccine Technology and ... Bird Flu ... March 31, 2008, IRVING, Texas, March 31 Carrington,Laboratories, Inc. ... net loss of $9.8 million, or ($0.90) per basic and,diluted share, ...
... Inc. (NYSE: CRY ),(the "Company"), a biomaterials, ... entered into a credit facility with GE Healthcare,Financial ... in revolving,credit for working capital, acquisitions and other ... at which time the outstanding,principal balance will be ...
Cached Biology Technology:Naglazyme Approved by Japanese Ministry of Health 2Naglazyme Approved by Japanese Ministry of Health 3Naglazyme Approved by Japanese Ministry of Health 4Carrington Reports 2007 Financial Results 2Carrington Reports 2007 Financial Results 3Carrington Reports 2007 Financial Results 4Carrington Reports 2007 Financial Results 5Carrington Reports 2007 Financial Results 6Carrington Reports 2007 Financial Results 7CryoLife Closes on $15 Million Credit Facility with GE Healthcare Financial Services 2CryoLife Closes on $15 Million Credit Facility with GE Healthcare Financial Services 3
(Date:10/15/2014)... Oct. 15, 2014   Neurotechnology , a ... the availability of the VeriLook Surveillance 3.0 ... provides real-time biometric face identification using live video ... cameras. The new version not only identifies faces ... from objects while they are moving through the ...
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... house fly genome for the first time, revealing robust ... that thrives in pathogen-rich dung piles and garbage heaps. ... Genome Biology , will increase understanding of house ... adapt to resist insecticides, which could lead to novel ... and transmit more than 100 human and animal diseases, ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2House fly genome reveals expanded immune system 2
... understand extreme sea creaturesExtraordinary creatures who inhabit extreme underwater ... three-year project. These deep-sea communities could reveal an evolutionary ... give us clues to how life could exist onother ... - incredibly hot environments in the deep sea - ...
... how Listeria monocytogenes, which causes a major ... and hide from the body's immune system. They believe ... , The Listeria bacterium, found in ... undercooked and unpasteurized food, causing flu-like symptoms or gastrointestinal ...
... blood pressure-lowering gene into cells and enables that gene to ... to take gene therapy for the disorder a step closer ... a report released online in the Proceedings of the National ... the leading causes of death and disability in adults worldwide," ...
Cached Biology News:Gene discovery sheds light on causes of rare disease, cancer 2Gene therapy to lower blood pressure just enough 2